WallStSmart
BHVN

Biohaven Ltd.

NYSE: BHVN · HEALTHCARE · BIOTECHNOLOGY

$12.71
-0.63% today

Updated 2026-09-11

Market cap
$1.93B
P/E ratio
P/S ratio
EPS (TTM)
$-4.55
Dividend yield
52W range
$7 – $19
Volume
2.6M

WallStSmart proprietary scores

23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
4.0
Quality
C
3.0
Profitability
D
5.0
Valuation
C+
1/9
Piotroski F-Score
Weak
-11.1
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →251 stocks currently score above 75

Price targets

Analyst target
$21.47
+68.92%
12-Month target
Intrinsic (DCF)
Margin of safety
4 Strong Buy9 Buy2 Hold0 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -11.11 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-85.55M
- Debt/equity 24.30x — high leverage

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-570.28M$-408.17M$-846.42M$-738.82M$-137.31M
EPS$-4.55
Free cash flow$-338.76M$-334.77M$-586.50M$-610.15M$-85.55M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
BHVN$1.93B234.33.05.04.0Avoid
LLY$994.92B769.310.05.06.0Strong Buy
JNJ$640.02B594.78.52.76.0-88.93%Buy
ABBV$454.36B736.78.54.05.0-69.36%Strong Buy
MRK$355.10B364.04.52.05.0-73.74%Hold
UNH$340.27B627.35.54.76.0-16.10%Buy

Smart narrative

Biohaven Ltd. trades at $12.71. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -11.11, it sits in the distress.

Frequently asked questions

What is Biohaven Ltd.'s stock price?

Biohaven Ltd. (BHVN) trades at $12.71.

Is Biohaven Ltd. overvalued?

Biohaven Ltd. carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Biohaven Ltd. (BHVN)?

The 12-month analyst consensus target is $21.47, about 68.9% above the current $12.71. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Biohaven Ltd.'s Altman Z-Score is -11.11, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE
CurrencyUSD

Quick metrics

P/S ratio
ROE-500.14%
Beta3.17
50D MA$14.83
200D MA$11.77
Shares out0.15B
Float0.12B
Short ratio
Avg volume2.6M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years